Meningococcal vaccine group C conjugate - Pfizer

Drug Profile

Meningococcal vaccine group C conjugate - Pfizer

Alternative Names: Meningococcal vaccine group C conjugate - Baxter; NeisVac; NeisVac-C

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator North American Vaccine
  • Developer Baxter International; Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 07 Apr 2015 The vaccine is approved for Meningococcal group C infections in Colombia
  • 30 Jul 2014 Pfizer acquires Baxter's commercial vaccine business, including meningococcal vaccine group C conjugate NeisVac-C
  • 18 Feb 2013 Discontinued - Phase-III for Meningococcal group C infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top